Profile Image

Staff Profile

Edit

Career Summary

Qualifications

  • Master of Surgery, University of Melbourne
  • Bachelor of Medicine & Surgery, University of Melbourne
  • Bachelor of Medical Science, University of Melbourne

Research

Research keywords

  • breast cancer clinical trials
  • breast cancer prevention & treatment

Research expertise

Professor Forbes is an internationally renowned researcher in the field of breast cancer prevention and treatment.

His experience with clinical trials in general and breast cancer trials in particular, extends from the creation of the Australian New Zealand Breast Cancer Trials Group (based in Newcastle, NSW), and coordination of Australias first multi-centre trial (ANZ 7801/02) in 1978, through more than 49 protocols for prevention of breast cancer and treatment of all stages of the disease. Professor Forbes has received continued NHMRC Project Grant support since 1979, and more than 600 publications have resulted from the ANZ BCTGs clinical trials program and research collaborations.

He is a Member of International Steering Committees for specific neo-adjuvant and adjuvant trials and international Advisory Boards, he is a member of numerous Editorial Boards, and a foundation member of the International Breast Cancer Study Group (Switzerland), as well as the Da Costa Advisory Board for prevention research (USA). In 2007 Professor Forbes was named by Thomson Scientific as one of the top 10 researchers globally (all fields), for papers cited in peer reviewed journals

Fields of Research

CodeDescriptionPercentage
111200Oncology And Carcinogenesis85
111599Pharmacology And Pharmaceutical Sciences Not Elsewhere Classified15

Memberships

Committee/Associations (relevant to research).

  • Inaugural Member - Da Costa Breast Cancer Foundation (USA)
  • Member - Advisory Committee, Early Breast Cancer Trialists' Group (UK)
  • Member - American Society of Clinical Oncology (ASCO)
  • Member of Council - Breast International Group (BIG)
  • Member - International Breast Cancer Study Group (Switzerland)
  • Member - International Exemestane Study (IES), International Steering Committee
  • Co-Chair - International Steering Committee, IBIS (Breast Cancer Prevention) Trial (UK)
  • Member - NSW Oncology Group Breast Steering Committee
  • Vice Chair - Scientific Advisory Committee, ANZ Breast Cancer Trials Group
  • Member - Scientific Advisory Committee, International Breast Cancer Study Group (Switzerland)

Learned Academy.

  • Life Member - Graduate Society, University of Melbourne

NHMRC Committee

  • Member - NHMRC Project Grants Assessor and Panel

Other

  • Inaugural Member, Board of Directors - ANZ Breast Cancer Trials Group Ltd
  • Inaugural Member - International Breast Cancer Study Group (Switzerland)

Appointments

Director
BreastScreen NSW Hunter New England (Australia)
01/01/1987 - 01/01/2006
Chair
ATAC International Steering Committee (United Kingdom)
01/01/2007

Awards

Recognition.

2007Top Ten Global Researchers in Publications 2005-2006
Thomson Scientific (United States)
1968Exhibition in Medicine (first place)
University of Melbourne (Australia)
1968Keith Levi Memorial Scholarship for Medicine (first place)
University of Melbourne (Australia)
1968Robert Gartley Healy Price in Medicine
University of Melbourne (Australia)
Exhibition in Medicine (1st place)

Research Award.

2007HMRI Excellence in Research Award
Hunter Medical Research Institute (Australia)
1980John Mitchell Crouch Fellowship
Royal Australasian College of Surgeons (Australia)
1975Nuffield Foundation: Commonwealth Travelling Fellowship in Medicine (Australia)
University of Melbourne (Australia)

Invitations

29th Clinical Oncological Society of Australia Conference, Sydney
Clinical Oncological Society of Australia, Australia (Conference - unpaid)
2002
2nd National Breast Cancer Conference for Women with Breast Cancer, Melbourne
National Breast Cancer Centre, Australia (Conference - unpaid)
2004
2nd PacRim Breast & Prostate Cancer Conference, Palm Springs, CA
as above, United States (Conference - unpaid)
2005
3rd European Breast Cancer Conference, Barcelona
as above, Spain (Conference - unpaid)
2002
3rd PacRim Breast & Prostate Cancer Mtg, Fraser Island, Qld
as above, Australia (Conference - unpaid)
2006
6th International Surgical Update
as above, Oman (Conference - unpaid)
2006
7th International Conference on Adjuvant Therapy of Primary Breast Cancer, St Gallen
as above, Switzerland (Conference - unpaid)
2001
ACINDES Experts Mtg, Buenas Aires
Association for Health Research & Development , Argentina (Conference - unpaid)
2003
ANZ Breast Cancer Trials Group Annual Scientific Mtg, Adelaide
ANZ Breast Cancer Trials Group, Australia (Conference - unpaid)
2003
ANZ Breast Cancer Trials Group Annual Scientific Mtg, Cairns
ANZ Breast Cancer Trials Group, Australia (Conference - unpaid)
2006
ANZ Breast Cancer Trials Group Annual Scientific Mtg, Hamilton Island
ANZ Breast Cancer Trials Group, Australia (Conference - unpaid)
2001
ANZ Breast Cancer Trials Group Annual Scientific Mtg, Perth, WA
ANZ Breast Cancer Trials Group, Australia (Conference - unpaid)
2005
ANZ Breast Cancer Trials Group Annual Scientific Mtg, Sanctuary Cove
ANZ Breast Cancer Trials Group, Australia (Conference - unpaid)
2002
American Society of Clinical Oncology Annual Mtg, Atlanta
American Society of Clinical Oncology, United States (Conference - unpaid)
2006
Asia Pacific Summit Mtg, Shangahi
AstraZeneca, China (Conference - unpaid)
2004
Asia-Pacific Breast Cancer Summit
Novartis, Australia (Conference - unpaid)
2006
Australian Breast Cancer Conference, Melbourne
unknown, Australia (Conference - unpaid)
2004
BASO Breast Group Conference, Solihull
BASO Breast Group, United Kingdom (Conference - unpaid)
2002
Breast Cancer Consultative Conference, San Antonio
AstraZeneca, United States (Conference - unpaid)
2001
Breast Cancer Endocrine Conference, Narita
Japan Breast Cancer Society, Japan (Conference - unpaid)
2002
Breast Cancer Summit, Mumbai
AstraZeneca, India (Conference - unpaid)
2007
Breast Cancer Summit, Shanghai
AstraZeneca, China (Conference - unpaid)
2006
Breast International Group Scientific Meeting
Breast International Group, Switzerland (Conference - unpaid)
2007
Familial & Genetic Aspects of Cancer Conference, Barossa Valley
unknown, Australia (Conference - unpaid)
2002
Familial Cancer Conference: Research & Practice, Sth Stradbroke Is, Qld
unknown, Australia (Conference - unpaid)
2004
Global Breast Cancer Summit, Madrid
unknown, Spain (Conference - unpaid)
2003
Hunter Medical Research Institute Cancer Conference, Newcastle
Hunter Medical Research Institute/Uni of Newcastle, Australia (Conference - unpaid)
2004
Hunter Medical Research Institute Cancer Conference, Newcastle
Hunter Medical Research Institute/Uni of Newcastle, Australia (Conference - unpaid)
2006
Korean Breast Cancer Society Symposium, Cheju Island
Korean Breast Cancer Society, Korea, Democratic People's Republic Of (Conference - unpaid)
2006
Mt Alvernia Annual Medical Advances Conference
Mt Alvernia Hospital, Singapore (Conference - unpaid)
2004
Primary Therapy of Early Breast Cancer - 10th International Conference
as above, Switzerland (Conference - unpaid)
2007
Royal Australasian College of Surgeons Annual Scientific Mtg, Brisbane
Royal Australasian College of Surgeons, Australia (Conference - unpaid)
2003
Salick Annual Research Group Conference, Berkeley, CA
Salick Research Group, United States (Conference - unpaid)
2002
Sydney Breast Cancer Trials International Symposium, Sydney
unknown, Australia (Conference - unpaid)
2004
Taiwan Oncology Joint Cancer Conference, Taipei
Taiwan Oncology Group, Taiwan (Conference - unpaid)
2005
Invited Lecture Series, Beijing, Guangzhou, & Hangzhou
AstraZeneca , China (Lecture Series - unpaid)
2006
The Walter & Eliza Hall Institute Postgraduate Lecture Series Seminar
as above, Australia (Lecture Series Seminar - unpaid)
2007
AstraZeneca Education Mtg, Sydney
AstraZeneca, Australia (Meeting - unpaid)
2002
Breast Cancer International Research Group Investigator's Mtg, Atlanta
Breast Cancer International Research Group, United States (Meeting - unpaid)
2006
Breast Cancer Round Table Mtg, Houston, Texas
AstraZeneca, United States (Meeting - unpaid)
2005
European Group Breast Cancer Screening Scientific Mtg, Barcelona
European Breast Cancer Screening Group, Spain (Meeting - unpaid)
2002
Evista Scientific Advisory Board Mtg, Chicago, Il
unknown, United States (Meeting - unpaid)
2003
Faslodex Study 25 Investigators Mtg, Barcelona
unknown, Spain (Meeting - unpaid)
2002
Leaders in BreastCARE Inaugural Meeting, Athens
as above, Greece (Meeting - unpaid)
2005
National Cancer Centre Mtg
National Cancer Centre, Singapore, Singapore (Meeting - unpaid)
2004
AstraZeneca Satellite Symposium, St Gallen
AstraZeneca, Switzerland (Symposium - unpaid)
2003
New Perspectives for Women with Breast Cancer Symposium
as above, Switzerland (Symposium - unpaid)
2005
Recent Advances in Breast Cancer Research Symposium, Sydney
unknown, Australia (Symposium - unpaid)
2002
2nd Novartis Workshop - Endocrine Therapy in Breast Cancer, Gleneagles
Novartis, United Kingdom (Workshop - unpaid)
2001

Administrative

Administrative expertise

Professor Forbes has had extensive administration experience for more than 20 years. He has been the Director of the Operations Office, and Group Coordinator of the Australian New Zealand Breast Cancer Trials Group since 1987. He helped establish the breast screening program in the Hunter Valley in 1987 and was Director of the program until 2006.

Teaching

Teaching keywords

  • breast disease
  • breast surgery

Teaching expertise

Professor Forbes has had 30 years teaching experience at the University of Melbourne and the University of Newcastle, and their respective teaching hospitals, with both undergraduate and overgraduate students and research staff.

Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Click on a category title below to expand the list of citations for that specific category.

Chapter (8 outputs)

YearCitationAltmetricsLink
2010Forbes JF, 'Overview and Future Perspectives of Primary Breast Cancer', Local and Systemic Management of Primary Breast Cancers, Kyoto University Press, Kyoto 3-17 (2010)
2009Ochsner A, Augustin C, 'Introduction', Multifunctional Metallic Hollow Sphere Structures: Manufacturing, Properties and Application, Springer, Berlin 1-4 (2009) [B2]

Citations: Scopus - 0

2007Forbes JF, 'Antiestrogens', Endocrine Therapies in Breast Cancer, Oxford University Press, Oxford 29-36 (2007) [B1]
2006Perez EA, Forbes JF, 'Introduction', 1-1 (2006)

DOI: 10.1053/j.seminoncol.2006.03.023

Citations: Scopus - 0

2003Forbes JF, 'Breast cancer', Evidence-Based Oncology, BMJ, London 429-464 (2003) [B1]
2002Forbes JF, 'Tamoxifen and Advanced Breast Cancer: an Overview', Endocrine Therapy in Breast Cancer, Marcell Dekker, New York 17-31 (2002)
1997Forbes JF, 'Current Role of the Surgeon in Collaborating with Medical Oncologists', Textbook of Breast Cancer: a Clinical Guide to Therapy, Dunitz, London 77-94 (1997)
1996Forbes JF, 'Screening for Breast Cancer and Treatment of Early Lesions (ductal carcinoma in situ): Summary', Adjuvant Therapy of Breast Cancer V, Springer, Berlin 155-157 (1996)
Show 5 more

Journal article (205 outputs)

YearCitationAltmetricsLink
2014Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al., 'Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial', LANCET, 383 1041-1048 (2014) [C1]

DOI: 10.1016/S0140-6736(13)62292-8 | Author URL

Citations: Scopus - 6 | Web of Science - 11

2014McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, et al., 'Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)', BREAST, 23 142-151 (2014) [C1]

DOI: 10.1016/j.breast.2013.12.001 | Author URL

Citations: Scopus - 0

2014Juraskova I, Butow P, Bonner C, Bell ML, Smith AB, Boyle F, et al., 'Improving decision making about clinical trial participation-a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial', British Journal of Cancer, 111 1-7 (2014)

DOI: 10.1038/bjc.2014.144

Citations: Scopus - 0

2014Avery-Kiejda KA, Mathe A, Scott RJ, Braye SG, Forbes JF, 'Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer', BMC Cancer, 14 (2014)

DOI: 10.1186/1471-2407-14-51

Citations: Scopus - 1 | Web of Science - 1

Co-authors: Kelly Kiejda, Rodney Scott

2014Huober J, Thürlimann B, Cole BF, Wu J, Giobbie-Hurder A, Price KN, et al., 'Symptoms of endocrine treatment and outcome in the BIG 1-98 study', Breast Cancer Research and Treatment, 143 159-169 (2014)

DOI: 10.1007/s10549-013-2792-7

Citations: Scopus - 1 | Web of Science - 1

2014Juraskova I, Butow P, Bonner C, Bell ML, Smith AB, Seccombe M, et al., 'Improving decision making about clinical trial participation - a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial', British Journal of Cancer, (2014)

DOI: 10.1038/bjc.2014.144

Citations: Scopus - 0

2014Avery-Kiejda KA, Braye SG, Forbes JF, Scott RJ, 'The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer.', BMC Cancer, 14 253 (2014)

DOI: 10.1186/1471-2407-14-253 | Author URL

Citations: Scopus - 1 | Web of Science - 1

Co-authors: Kelly Kiejda, Rodney Scott

2013Lee C, Gebski VJ, Coates AS, Veillard A-S, Harvey V, Tattersall MHN, et al., 'Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone', SpringerPlus, 2 (2013) [C1]

DOI: 10.1186/2193-1801-2-391

Citations: Scopus - 0

2013Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al., 'Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results', ANNALS OF ONCOLOGY, 24 398-405 (2013) [C1]

DOI: 10.1093/annonc/mds277 | Author URL

Citations: Scopus - 29 | Web of Science - 25

2013Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al., 'Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data', LANCET, 381 1827-1834 (2013) [C1]

DOI: 10.1016/S0140-6736(13)60140-3 | Author URL

Citations: Scopus - 32 | Web of Science - 28

2013Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al., 'Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013', Annals of Oncology, 24 2206-2223 (2013) [C1]

DOI: 10.1093/annonc/mdt303

Citations: Scopus - 91

2013Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, et al., 'Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study', BREAST CANCER RESEARCH AND TREATMENT, 140 253-262 (2013) [C1]

DOI: 10.1007/s10549-013-2628-5 | Author URL

Citations: Scopus - 1 | Web of Science - 1

2013Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al., 'Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial', LANCET, 381 805-816 (2013) [C1]

DOI: 10.1016/S0140-6736(12)61963-1 | Author URL

Citations: Scopus - 131 | Web of Science - 110

2012Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, et al., 'Disease-related outcomes with long-term follow-up: An updated analysis of the Intergroup Exemestane Study', Journal of Clinical Oncology, 30 709-717 (2012) [C1]

DOI: 10.1200/JCO.2010.33.7899

Citations: Scopus - 25 | Web of Science - 21

2012Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J, 'Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer', Breast Cancer Research and Treatment, 134 727-734 (2012) [C1]

DOI: 10.1007/s10549-012-2085-6

Citations: Scopus - 4 | Web of Science - 2

2012Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes JF, Howell A, Cuzick J, 'Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial', British Journal of Cancer, 107 230-233 (2012) [C1]

Citations: Scopus - 3 | Web of Science - 3

2012Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson JFR, et al., 'The sequential use of endocrine treatment for advanced breast cancer: Where are we?', Annals of Oncology, 23 1378-1386 (2012) [C1]

Citations: Scopus - 14 | Web of Science - 11

2012Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thurlimann B, et al., 'Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial', Journal of Clinical Oncology, 30 3967-3975 (2012) [C1]

Citations: Scopus - 16 | Web of Science - 16

2012Karlsson P, Cole BF, Chua BH, Price KN, Lindtner J, Collins JP, et al., 'Patterns and risk factors for locoregional failures after mastectomy for breast cancer: An International Breast Cancer Study Group Report', Annals of Oncology, 23 2852-2858 (2012) [C1]

Citations: Scopus - 4 | Web of Science - 5

2012Toi M, Benson JR, Winer EP, Forbes JF, Von Minckwitz G, Golshan M, et al., 'Preoperative systemic therapy in locoregional management of early breast cancer: Highlights from the Kyoto Breast Cancer Consensus Conference', Breast Cancer Research and Treatment, 136 919-926 (2012) [C2]

Citations: Scopus - 2 | Web of Science - 1

2011Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, et al., 'Influence of comorbidities and age on risk of death without recurrence: A retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination Trial', Journal of Clinical Oncology, 29 4266-4272 (2011) [C1]

Citations: Scopus - 26 | Web of Science - 22

2011Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al., 'Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: Long-term results from the UK/ANZ DCIS trial', The Lancet Oncology, 12 21-29 (2011) [C1]

DOI: 10.1016/s1470-2045(10)70266-7

Citations: Scopus - 86 | Web of Science - 70

2011Valero V, Forbes JF, Pegram MD, Pienkowski T, Eiermann W, Von Minckwitz G, et al., 'Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 Study): Two highly active therapeutic regimens', Journal of Clinical Oncology, 29 149-156 (2011) [C1]

DOI: 10.1200/JCO.2010.28.6450

Citations: Scopus - 77 | Web of Science - 57

2011Colleoni M, Giobbie-Hurder A, Regan MM, Thurlimann B, Mouridsen H, Mauriac L, et al., 'Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study', Journal of Clinical Oncology, 29 1117-1124 (2011) [C1]

Citations: Scopus - 47 | Web of Science - 42

2011Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, et al., 'Predictive algorithms for adjuvant therapy: TransATAC', Steroids, 76 777-780 (2011) [C1]

Citations: Scopus - 14 | Web of Science - 12

2011Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al., 'Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: A nested case-control study', Journal of the National Cancer Institute, 103 744-752 (2011) [C1]

DOI: 10.1093/jnci/djr079

Citations: Scopus - 86 | Web of Science - 74

2011Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland S, Fitzharris B, et al., 'Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer', Journal of Clinical Oncology, 29 4498-4504 (2011) [C1]

Citations: Scopus - 30 | Web of Science - 20

Co-authors: Stephen Ackland

2011Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al., 'Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and comparison with the Genomic Health Recurrence Score in early breast cancer', Journal of Clinical Oncology, 29 4273-4278 (2011) [C1]

DOI: 10.1200/jco.2010.31.2835

Citations: Scopus - 146 | Web of Science - 128

2011Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, et al., 'Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up', Lancet Oncology, 12 1101-1108 (2011) [C1]

Citations: Scopus - 67 | Web of Science - 57

2011Forbes JF, Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, 'Strategies for Subtypes - Dealing with the Diversity of Breast Cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011', Annals of Oncology, 22 1376-1347 (2011) [C1]

DOI: 10.1093/annonc/mdr304

Citations: Scopus - 695

2011Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, et al., 'Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial', Annals of Oncology, 22 2201-2207 (2011) [C1]

DOI: 10.1093/annonc/mdq738

Citations: Scopus - 30 | Web of Science - 21

2011Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, et al., 'Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence score alone and integrated with pathologic and clinical factors', Journal of Clinical Oncology, 29 4365-7372 (2011) [C1]

DOI: 10.1200/jco.2011.35.3714

Citations: Scopus - 27 | Web of Science - 22

2011Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, et al., 'Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto Consensus Conference', Annals of Surgical Oncology, 18 2885-2892 (2011) [C1]

DOI: 10.1245/s10434-011-1666-7

Citations: Scopus - 4 | Web of Science - 4

2011Cuzick J, Decensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al., 'Preventive therapy for breast cancer: A consensus statement', The Lancet Oncology, 12 496-503 (2011) [C1]

Citations: Scopus - 80 | Web of Science - 68

2011Loi S, Symmans WF, Bartlett JMS, Fumagalli D, Van'T Veer L, Forbes JF, et al., 'Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: Timing and specimen types', The Lancet Oncology, 12 1162-1168 (2011) [C2]

Citations: Scopus - 1 | Web of Science - 1

2011Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, '10-year analysis of the ATAC trial: Wrong conclusion? - Authors' reply', The Lancet Oncology, 12 217 (2011) [C3]

DOI: 10.1016/s1470-2045(11)70050-x

Citations: Scopus - 2 | Web of Science - 1

2011Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick JM, 'Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it', JOURNAL OF CLINICAL ONCOLOGY, 29 (2011) [E3]
2011Huober JB, Cole BF, Wu J, Giobbie-Hurder A, Rabaglio M, Mouridsen HT, et al., 'Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial', JOURNAL OF CLINICAL ONCOLOGY, 29 (2011) [E3]
2011Kiely BE, Phillips K, Francis PA, Boyle FM, Forbes JF, Fox SB, et al., 'ANZ1001 SORBET: Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen-A single-arm, phase II study of the efficacy of tamoxifen in triple-negative but estrogen receptor beta-positive metastatic breast cancer.', JOURNAL OF CLINICAL ONCOLOGY, 29 (2011) [E3]
2010Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H, et al., 'A new pathological system for grading DCIS with improved prediction of local recurrence: Results from the UKCCCR/ANZ DCIS Trial', British Journal of Cancer, 103 94-100 (2010) [C1]

DOI: 10.1038/sj.bjc.6605718

Citations: Scopus - 25 | Web of Science - 22

2010Dowsett M, Cuzick J, Ingle J, Coates A, Forbes JF, Bliss J, et al., 'Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus Tamoxifen', Journal of Clinical Oncology, 28 509-518 (2010) [C1]

DOI: 10.1200/JCO.2009.23.1274

Citations: Scopus - 238 | Web of Science - 204

2010Dowsett M, Cuzick J, Wale C, Forbes JF, Mallon EA, Salter J, et al., 'Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC Study', Journal of Clinical Oncology, 28 1829-1834 (2010) [C1]

DOI: 10.1200/JCO.2009.24.4798

Citations: Scopus - 152 | Web of Science - 133

2010Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J, 'Effect of body mass index on recurrences in Tamoxifen and Anastrozole treated women: An exploratory analysis from the ATAC trial', Journal of Clinical Oncology, 28 3411-3415 (2010) [C1]

DOI: 10.1200/jco.2009.27.2021

Citations: Scopus - 85 | Web of Science - 77

2010Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, 'Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial', The Lancet Oncology, 11 1135-1141 (2010) [C1]

DOI: 10.1016/S1470-2045(10)70257-6

Citations: Scopus - 191 | Web of Science - 167

2010Forbes JF, Tang G, Cuzick J, Wale C, Costantino JP, Crager M, et al., 'Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach', Journal of Clinical Oncology, 28 s509 (2010) [E3]
2010Tang G, Cuzick J, Wale C, Costantino JP, Crager M, Shak S, et al., 'Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach', JOURNAL OF CLINICAL ONCOLOGY, 28 (2010) [E3]
2009Green MD, Francis PA, Gebski V, Harvey V, Karapetis C, Chan A, et al., 'Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer', Annals of Oncology, 20 1813-1817 (2009) [C1]

DOI: 10.1093/annonc/mdp202

Citations: Scopus - 27 | Web of Science - 26

2009Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thurlimann B, et al., 'Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial', Annals of Oncology, 20 1489-1498 (2009) [C1]

DOI: 10.1093/annonc/mdp033

Citations: Scopus - 59 | Web of Science - 51

2009Thurlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, et al., 'Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93', Breast Cancer Research and Treatment, 113 137-144 (2009) [C1]

DOI: 10.1007/s10549-008-9912-9

Citations: Scopus - 29 | Web of Science - 27

2009Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, et al., 'Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93', Breast Cancer Research and Treatment, 116 491-500 (2009) [C1]

DOI: 10.1007/s10549-008-0225-9

Citations: Scopus - 21 | Web of Science - 20

2009Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thurlimann B, Paridaens R, Smith I, et al., 'Letrozole therapy alone or in sequence with Tamoxifen in women with breast cancer', New England Journal of Medicine, 361 766-776 (2009) [C1]

DOI: 10.1056/NEJMoa0810818

Citations: Scopus - 235 | Web of Science - 201

2008Atac Trialists' Group, Forbes JF, 'Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial', Lancet Oncology, 9 45-53 (2008) [C1]

DOI: 10.1016/s1470-2045(07)70385-6

Citations: Scopus - 84 | Web of Science - 86

2008Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al., 'Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial', Journal of Clinical Oncology, 26 1059-1065 (2008) [C1]

DOI: 10.1200/jco.2007.12.9437

Citations: Scopus - 207 | Web of Science - 189

2008Crivellari D, Sun Z, Coates AS, Price KN, Thurlimann B, Mouridsen H, et al., 'Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The BIG 1-98 trial', Journal of Clinical Oncology, 26 1972-1979 (2008) [C1]

DOI: 10.1200/jco.2007.14.0459

Citations: Scopus - 73 | Web of Science - 58

2008Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU, 'Risk factors for joint symptoms in patients enrolled in the ATAC trial: A retrospective, exploratory analysis', Lancet Oncology, 9 866-872 (2008) [C1]

DOI: 10.1016/s1470-2045(08)70182-7

Citations: Scopus - 80 | Web of Science - 73

2008Juraskova I, Butow P, Lopez A, Seccombe MA, Coates A, Boyle F, et al., 'Improving informed consent: Pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS)', Health Expectations, 11 252-262 (2008) [C1]

DOI: 10.1111/j.1369-7625.2008.00498.x

Citations: Scopus - 24 | Web of Science - 24

2008Bernhard J, Zahrieh D, Zhang JJ, Martinelli G, Basser R, Hurny C, et al., 'Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer', British Journal of Cancer, 98 25-33 (2008) [C1]

DOI: 10.1038/sj.bjc.6604092

Citations: Scopus - 9 | Web of Science - 7

2008Leyland-Jones BR, Ambrosone CB, Bartlett J, Ellis MJC, Enos RA, Raji A, et al., 'Recommendations for collection and handling of specimens from group breast cancer clinical trials', Journal of Clinical Oncology, 26 5638-5644 (2008) [C1]

DOI: 10.1200/jco.2007.15.1712

Citations: Scopus - 44 | Web of Science - 44

2008Gao J, Warren R, Warren-Forward H, Forbes JF, 'Reproducibility of visual assessment on mammographic density', Breast Cancer Research and Treatment, 108 121-127 (2008) [C1]

DOI: 10.1007/s10549-007-9581-0

Citations: Scopus - 18 | Web of Science - 17

Co-authors: Helen Warren-Forward

2008Forbes JF, Buchanan D, Coates A, Piccart M, Trudeau M, Saghir N, et al., 'International Trends and Challenges in Breast Cancer as Perceived by Leaders in Medicine, Public Policy and Advocacy', American Journal of Clinical Oncology: cancer clinical trials, 31 510 (2008)
2007Thurliumann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, Wallgren A, et al., 'The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer', Journal of Clinical Oncology, 25 2019-2026 (2007) [C1]

DOI: 10.1200/JCO.2006.09.8152

Citations: Scopus - 24 | Web of Science - 21

2007The International Breast Cancer Study Group, Forbes JF, 'Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93', Annals of Oncology, 18 1177-1184 (2007) [C1]

DOI: 10.1093/annonc/mdm091

Citations:

2007Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, 'Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial', Journal of the National Cancer Institute, 99 272-282 (2007) [C1]

DOI: 10.1093/jnci/djk049

Citations: Scopus - 257 | Web of Science - 222

2007Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes JF, Thurlimann B, et al., 'Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial', Annals of Oncology, 18 859-867 (2007) [C1]

DOI: 10.1093/annonc/mdm001

Citations: Scopus - 103 | Web of Science - 90

2007Coombes R, Kilburn L, Snowdon C, Paridaens R, Coleman R, Jones S, et al., 'Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial', Lancet, 369 559-570 (2007) [C1]

DOI: 10.1016/S0140-6736(07)60200-1

Citations: Scopus - 538 | Web of Science - 480

2007Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, et al., 'Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model', Endocrine-Related Cancer, 14 169-187 (2007) [C1]

DOI: 10.1677/ERC-06-0045

Citations: Scopus - 86 | Web of Science - 72

2007Easton DF, Search Collaborators Including, Forbes JF, 'Genome-wide association study identifies novel breast cancer susceptibility loci', Nature, 447 1087-1093 (2007) [C1]

DOI: 10.1038/nature05887

Citations: Scopus - 1240

Co-authors: Rodney Scott

2007Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, et al., 'Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 Trial', Journal of Clinical Oncology, 25 5715-5722 (2007) [C1]

DOI: 10.1200/jco.2007.12.1665

Citations: Scopus - 70 | Web of Science - 53

2007Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al., 'Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98', Journal of Clinical Oncology, 25 486-492 (2007) [C1]

DOI: 10.1200/JCO.2006.08.8617

Citations: Scopus - 568 | Web of Science - 508

2007Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hurny C, Gelber RD, Forbes JF, et al., 'Adjuvant chemotherapy followed by goserelin compared with either modality alone: The impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--The International Breast Cancer Study Group Trial VIII', Journal of Clinical Oncology, 25 263-270 (2007) [C1]

DOI: 10.1200/jco.2005.04.5393

Citations: Scopus - 28 | Web of Science - 26

2007Juraskova I, Butow P, Lopez AL, Seccombe MA, Boyle F, McCarthy N, Forbes JF, 'Improving informed consent in clinical trials: Successful piloting of a decision aid', Journal of Clinical Oncology, 25 1443-1444 (2007) [C3]

Citations: Scopus - 11 | Web of Science - 10

2007Forbes JF, 'Controversies in the use of sentinel nodes in the elderly', BREAST, 16 S5-S6 (2007)

DOI: 10.1016/S0960-9776(07)70042-5 | Author URL

Citations: Web of Science - 1

2006Carl-Magnus R, Forbes JF, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS, 'Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older patients With Breat Cancer: First Results of International Breast Cancer Study Group Trial 10-93', journal of Clinical Oncology, 24 337-344 (2006) [C1]

DOI: 10.1200/JCO.2005.01.5784

Citations: Scopus - 126 | Web of Science - 102

2006Forbes JF, 'The Use of Early Adjuvant Aromatase Inhibitor Therapy: Contributions From the BIG 1-98 Letrozole Trial', Seminars in Oncology, 33 S2-S7 (2006) [C1]

DOI: 10.1053/j.seminoncol.2006.03.026

Citations: Scopus - 7 | Web of Science - 4

2006Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes JF, Jonat W, Ravdin P, 'Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer', Current Medical Research and Opinion, 22 1575-1585 (2006) [C1]

DOI: 10.1185/030079906X120940

Citations: Scopus - 22

2006Sestak I, Kealy R, Edwards R, Forbes JF, Cuziack J, 'Influence of Hormone Replacement Therapy on Tamoxifen-Induced Vasomotor Symptoms', Journal of Clinical Oncology, 24 3991-3996 (2006) [C1]

DOI: 10.1200/JCO.2005.04.3745

Citations: Scopus - 30 | Web of Science - 25

2006Cuzick J, Forbes JF, Howell A, 'Re: Tamoxifen for the prevention of breast cancer: Current status of the national surgical adjuvant breast and bowel project P-1 study (Letter)', Journal of the National Cancer Institute, 98 643 (2006) [C3]

Citations: Scopus - 4 | Web of Science - 3

2006Juraskova I, Butow P, Lopez AL, Seccombe M, Forbes J, 'Improving informed consent to clinical trials: A pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II)', PSYCHO-ONCOLOGY, 15 S280-S281 (2006)
2006Forbes JF, 'The Australia New Zealand Breast Cancer Trials Group: Some contributions to breast cancer trials', Cancer Forum, 30 118-121 (2006)

Citations: Scopus - 0

2006Forbes JF, Mourisden HT, Keshavia A, Mauriac L, Paridaens R, Castiglione-Gertsch M, Goldhirsch A, 'BIG 1-98: A Randomized double-blind Phase III Study Comparing Letrozole and Tamoxifen given in Sequence vs. Alone as Adjuvant Endocrine Therapy for Postmenopausal Women with Receptor-Positive Breast Cancer', Journal of Clinical Oncology, 24 10s (2006)
2006Perez EA, Forbes JF, 'From tamoxifen to letrozole: Changing paradigms for the treatment of hormone-sensitive breast cancer - Introduction', SEMINARS IN ONCOLOGY, 33 S1-S1 (2006)
2006Duffy S, Lansdown M, Jackson TL, Philips K, Phillips K, Wells M, et al., 'The ATAC ('Arimidex', tamoxifen, alone or in combination) adjuvant breast cancer trial: First results of the endometrial sub-protocol following 2 years of treatment', Human Reproduction, 21 545-553 (2006)

DOI: 10.1093/humrep/dei322

Citations: Scopus - 44

2005Thurlimann B, Kehsaviah A, Coates A, Mouridsen H, Mauriac L, Forbes JF, et al., 'A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer', New England Journal of Medicine, 353 2747-2758 (2005) [C1]

DOI: 10.1056/NEJMoa052258

Citations: Scopus - 973 | Web of Science - 851

2005Colleoni M, Li S, Gelber RD, Coates AS, Castiglione-Gertsch M, Price KN, et al., 'Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor', Annals of Oncology, 16 716-725 (2005) [C1]

DOI: 10.1093/annonc/mdi163

Citations: Scopus - 15 | Web of Science - 12

2005Forbes JF, Early Breast Cancer Trialists' CGE, 'Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials', Lancet, 366 2087-2106 (2005) [C1]

Citations: Scopus - 2076

2005Forbes JF, 'Letrozole vs. Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women with Receptor-Positive Breast Cancer. BIG 1-98: A Prospective Randomized Double-Blind Phase III Study', The Breast, 14 (2005) [C1]
2005Forbes JF, 'Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-year Survival: an Overview of the Randomized Trials', The Lancet, 365 1687-1717 (2005) [C1]
2005Forbes JF, Cuzick J, 'Systemic Adjuvant Therapies for Early Breast Cancer: 15-year Results for Recurrence and Survival', Medical Journal of Australia, 183 447-448 (2005) [C2]

Citations: Scopus - 0

2005Cuzick J, Howell A, Forbes JF, 'Early stopping of clinical trials (Commentary)', Breast Cancer Research, 7 181-183 (2005) [C3]

Citations: Scopus - 8 | Web of Science - 7

2005Forbes JF, 'Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial After Completion of 5 years' Adjuvant Treatment for Breast Cancer', The Lancet, 365 60-62 (2005) [C3]

Citations: Web of Science - 1188

2004Bernhard J, Zahrieh D, Coates AS, Gelber RD, Castiglione-Gertsch M, Murray E, et al., 'Quantifying trade-offs: Quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer', British Journal of Cancer, 91 1893-1901 (2004) [C1]

DOI: 10.1038/sj.bjc.6602230

Citations: Scopus - 17 | Web of Science - 16

2004Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, et al., 'Adjuvant use of anastrozole in breast cancer', JOURNAL OF CLINICAL ONCOLOGY, 22 1524-1526 (2004)

DOI: 10.1200/JCO.2004.99.165 | Author URL

Citations: Scopus - 1 | Web of Science - 4

2003Wallgren A, Bonetti M, Gelber R, Goldhirsch M, Castiglione-Gertsch S, Holmberg J, et al., 'Risk factors for Locoregional Recurrence Among Breast Cancer Patients: Results from international breast cancer study group I through VII', Journal of Clinical Oncology, 21 1205-1213 (2003) [C1]

DOI: 10.1200/JCO.2003.03.130

Citations: Scopus - 140 | Web of Science - 120

2003Cuzick J, Powles T, Veronesi U, Forbes JF, Edwards R, Ashley S, Boyle P, 'Overview of the main outcomes in breast-cancer prevention trials', The Lancet, 361 296-300 (2003) [C1]

DOI: 10.1016/S0140-6736(03)12342-2

Citations: Scopus - 662 | Web of Science - 518

2003Aapro MS, Forbes JF, 'Three years' follow-up from the ATAC trial is sufficient to change clinical practice: A debate', Breast Cancer Research and Treatment, 80 3-11 (2003) [C1]

DOI: 10.1023/a:1025455130476

Citations: Scopus - 10 | Web of Science - 4

2003Cuzick J, Forbes JF, Howell A, 'Tamoxifen for breast-cancer prevention', Lancet, 361 178 (2003) [C3]
2003Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, 'Anastrozole Alone or in Combination with Tamoxifen versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early-Stage Breast Cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial Efficacy and Safety Update Analyses', Cancer, 98 1802-1810 (2003)

DOI: 10.1002/cncr.11745

Citations: Scopus - 589

2003Cykert S, Caine GJ, Blann AD, Lip GYH, Stonelake PS, Kehoe ST, et al., 'Tamoxifen for breast-cancer prevention [3] (multiple letters)', Lancet, 361 177-178 (2003)

Citations: Scopus - 1

2003Cuzick J, O'Neill C, Howell T, Forbes J, 'Anastrozole for ductal carcinoma in situ [2]', Lancet, 362 832-833 (2003)

DOI: 10.1016/S0140-6736(03)14257-2

Citations: Scopus - 1

2003George WD, Houghton J, Austoker J, Bishop H, Cuzick J, Fentiman IS, et al., 'Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial', LANCET, 362 95-102 (2003)

Author URL

Citations: Web of Science - 285

2002Forbes JF, Gradishar W, Ravdin P, 'Choosing between endocrine therapy and chemotherapy - or is there a role for combination therapy?', Breast Cancer Research and Treatment, 75 S37-S44 (2002) [C1]

Citations: Scopus - 2 | Web of Science - 2

2002Forbes JF, 'Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial', The Lancet, 359 2131-2139 (2002)

DOI: 10.1016/S0140-6736(02)09088-8

Citations: Scopus - 1422

2002Forbes JF, 'Chemoprevention: Inside and outside trials', EUROPEAN JOURNAL OF CANCER, 38 S43-S44 (2002)
2002Forbes JF, 'Management of breast cancer risk - Screening versus prophylaxis', EUROPEAN JOURNAL OF CANCER, 38 S38-S39 (2002)
2002Forbes JF, 'First Results from the International Breast Cancer Intervention Study (IBIS-I): a Randomised Prevention Trial', The Lancet, 360 817-824 (2002)
2002Forbes JF, International Breast Cancer Study Group, 'Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial', Journal of the National Cancer Institute, 94 1054-1065 (2002)

DOI: 10.1093/jnci/94.14.1054

Citations: Web of Science - 80

2001Thurlimann B, Price K, Castiglione M, Coates A, Goldhirsch A, Gelber R, et al., 'Randomized controlled trial of ovarian function suppression plux tamoxifen verses the same endocrine therapy plus chemotherapy: is chemotherapynecessary for premonopausalwomen withnonde-positive, endocrine-responsive breast cancer? First results of Intern', The Breast, 10(Supplement3) 130-138 (2001) [C1]

Citations: Scopus - 47

2001Klijn JGM, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R, et al., 'Combined tamoxifen and luteinuzing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials', Journal of Clinical Oncology, 19 343-353 (2001)

Citations: Scopus - 282

2001Millar EKA, Pepperall D, Lee CS, Forbes JF, 're: p53 protein detection in breast epithelium by immunohistochemistry', BREAST, 10 263-265 (2001)

Author URL

Citations: Scopus - 0

2000Crivellari D, Bonetti M, Gastiglione-Gertsch M, Gelber R, Rudenstam C-M, Thurlimann B, et al., 'Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluoruoracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII', Journal of Clinical Oncology, 18 (7) 1412-1422 (2000) [C1]

Citations: Scopus - 226 | Web of Science - 181

2000Colleoni M, O'Neill A, Goldhirsch A, Gelber R, Bonetti M, Thurlimann B, et al., 'Identifying breast cancer patients at high risk for bone metastases', Journal of Clinical Oncology, 18 (23) 3925-3935 (2000) [C1]

Citations: Scopus - 59 | Web of Science - 52

2000Forbes JF, Early Breast Cancer Trialists' Collaborative Group, 'Favourable and Unfavourable Effects on Long-Term Survival of Radiotherapy for Early Breast Cancer: an Overview of the Randomised Trials', The Lancet, 355 1757-1770 (2000)
1999Forbes JF, 'Sequential Randomized Studies in Metastatic Breast Cancer: CMFP vs Doxorubicin / cyclophosphamide, mitoxantrone or paclitaxel', Oncology, 13 s7 (1999)
1998Bernhard J, Hurny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, et al., 'Factors affecting baseline quality of life in two international adjuvant breast cancer trials', BRITISH JOURNAL OF CANCER, 78 686-693 (1998)

DOI: 10.1038/bjc.1998.561 | Author URL

Citations: Scopus - 24 | Web of Science - 21

1998Forbes JF, Early Breast Cancer Trialists¿ Collaborative Group, 'Ploychemotherapy for Early Breast Cancer: an Overview of the Randomized Trials', The Lancet, 352 930-942 (1998)
1998Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Nomura Y, et al., 'Tamoxifen for early breast cancer: An overview of the randomised trials', Lancet, 351 1451-1467 (1998)

DOI: 10.1016/S0140-6736(97)11423-4

Citations: Scopus - 3155

1998Hui R, Ball JR, Macmillan RD, Kenny FS, Prall OWJ, Campbell DH, et al., 'EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival', ONCOGENE, 17 1053-1059 (1998)

DOI: 10.1038/sj.onc.1202023 | Author URL

Citations: Scopus - 64 | Web of Science - 65

1998Powell JT, Brady AR, Brown LC, Forbes JF, Fowkes FGR, Greenhalgh RM, et al., 'Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms', LANCET, 352 1649-1655 (1998)

Author URL

Citations: Scopus - 691 | Web of Science - 504

1998Rees B, Kelly K, Forbes J, 'The role of nurse counsellor support groups for women diagnosed with breast cancer at hunter breast screen', EUROPEAN JOURNAL OF CANCER, 34 S42-S42 (1998)
1997Forbes JF, 'The incidence of breast cancer: The Global Burden, public health considerations', SEMINARS IN ONCOLOGY, 24 S20-S35 (1997)

Author URL

Citations: Scopus - 72 | Web of Science - 3

1997Forbes JF, 'The control of breast cancer: The role of tamoxifen', SEMINARS IN ONCOLOGY, 24 S5-S19 (1997)

Author URL

Citations: Scopus - 58 | Web of Science - 1

1997Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, et al., 'An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer', BREAST CANCER RESEARCH AND TREATMENT, 44 201-210 (1997)

DOI: 10.1023/A:1005833811584 | Author URL

Citations: Scopus - 48 | Web of Science - 40

1997CastiglioneGertsch M, Goldhirsch A, Gusterson B, Bettelheim R, Reed R, Gusset H, et al., 'Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients', JOURNAL OF CLINICAL ONCOLOGY, 15 1385-1394 (1997)

Author URL

Citations: Web of Science - 94

1997Goldhirsch A, Gelber RD, Castiglione M, ONeill A, Thurlimann B, Rudenstam CM, et al., 'Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: Results of the International Breast Cancer Study Group (IBCSG) Trial VI', ANNALS OF ONCOLOGY, 8 751-756 (1997)

DOI: 10.1023/A:1008220301866 | Author URL

Citations: Scopus - 23 | Web of Science - 25

1997Byrne MJ, Gebski V, Forbes J, Tattersall MHN, Simes RJ, Coates AS, et al., 'Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: A phase III randomized trial', JOURNAL OF CLINICAL ONCOLOGY, 15 3141-3148 (1997)

Author URL

Citations: Scopus - 18 | Web of Science - 16

1996CastiglioneGertsch M, Goldhirsch A, Gusterson B, Bettelheim R, Reed R, Gussett H, et al., 'Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients', JOURNAL OF CLINICAL ONCOLOGY, 14 1885-1894 (1996)

Author URL

Citations: Web of Science - 72

1996Clarke M, Collins R, Davies C, Godwin J, Gray R, Peto R, et al., 'Ovarian ablation in early breast cancer: Overview of the randomised trials', LANCET, 348 1189-1196 (1996)

Author URL

Citations: Web of Science - 331

1996Forbes JF, Marini G, Murray S, Goldhirsch A, Gelber RD, Castiglione-Gertsch M, et al., 'The Effect of Adjuvant Prednisone Combined with CMF on Patterns of Relapse and Occurrence of Second Malignancies in Patients with Breast Cancer', Annals of Oncology, 7 245-250 (1996)

Citations: Scopus - 15

1996Forbes JF, Hürny C, Bernhard J, Castiglione-Gertsch M, Coates AS, Peterson HF, et al., 'Impact of Adjuvant Therapy on Quality of Life in Women with Node-positive Operable Breast Cancer', The Lancet, 347 1279-1284 (1996)

DOI: 10.1016/S0140-6736(96)90936-8

Citations: Scopus - 132 | Web of Science - 129

1996Rainsbury D, Kirkbride P, Vallis K, Kunkler I, Tierney A, Jodrell N, et al., 'Routine follow up of breast cancer in primary care [1]', British Medical Journal, 313 1547-1548 (1996)

Citations: Scopus - 3

1996Clover K, Redman S, Forbes J, SansonFisher R, Callaghan T, 'Two sequential randomized trials of community participation to recruit women for mammographic screening', PREVENTIVE MEDICINE, 25 126-134 (1996)

DOI: 10.1006/pmed.1996.0038 | Author URL

Citations: Scopus - 25 | Web of Science - 22

Co-authors: Rob Sanson-Fisher

1995NIU J, SHOU NH, FORBES JF, SUN XY, HU SY, LIU FJ, 'LAPAROSCOPIC EXPLORATION OF INTRAHEPATIC AND EXTRAHEPATIC BILE-DUCTS AND T-TUBE DRAINAGE', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 65 189-193 (1995)

DOI: 10.1111/j.1445-2197.1995.tb00605.x | Author URL

Citations: Scopus - 8 | Web of Science - 9

1995Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam C-M, Lindtner J, et al., 'The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study Group', Israel Journal of Medical Sciences, 31 144-154 (1995)

Citations: Scopus - 4

1995Forbes JF, Crivellari D, Price KN, Hagen M, Goldhirsch A, Gelber RD, et al., 'Routine tests during follow-up of patients after primary treatment for operable breast cancer', Annals of Oncology, 6 769-776 (1995)

Citations: Scopus - 20

1995ABE O, ABE R, ASAISHI K, ENOMOTO K, HATTORI T, IINO Y, et al., 'EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS', NEW ENGLAND JOURNAL OF MEDICINE, 333 1444-1455 (1995)

Author URL

Citations: Web of Science - 619

1995Forbes JF, Goldhirsch A, Gelber R, Castiglione M, Price KN, Fey M, et al., 'The best available adjuvant treatments are within the framework of clinical trials', Israel Journal of Medical Science, 31 144-154 (1995)
1995JONAT W, KAUFMANN M, BLAMEY RW, HOWELL A, COLLINS JP, COATES A, et al., 'A RANDOMIZED STUDY TO COMPARE THE EFFECT OF THE LUTEINIZING-HORMONE-RELEASING HORMONE (LHRH) ANALOG GOSERELIN WITH OR WITHOUT TAMOXIFEN IN PREMENOPAUSAL AND PERIMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER', EUROPEAN JOURNAL OF CANCER, 31A 137-142 (1995)

DOI: 10.1016/0959-8049(94)00415-2 | Author URL

Citations: Web of Science - 67

1994Forbes JF, Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, et al., 'A randomised trial comparing 'Zoladex' (Goserelin) with 'Nolvadex' (Tamoxifen) as first line treatment for premenopausal advanced breast cancer', Proceedings of the American Society of Clinical Oncology, 33 (1994)
1994Forbes JF, Simes RJ, Gebski V, Coates AS, Harvey V, van Hazel G, 'Quality of life (QoL) with single agent Mitozantrone (MTZ) or combination chemotherapy (CMFP) for advanced breast cancer: a randomised trial', Proceedings of the American Society of Clinical Oncology, 13 96 (1994)
1994GOLDHIRSCH A, GELBER RD, PRICE KN, CASTIGLIONE M, COATES AS, RUDENSTAM CM, et al., 'EFFECT OF SYSTEMIC ADJUVANT TREATMENT ON FIRST SITES OF BREAST-CANCER RELAPSE', LANCET, 343 377-381 (1994)

DOI: 10.1016/S0140-6736(94)91221-1 | Author URL

Citations: Scopus - 63 | Web of Science - 60

1994Forbes JF, Simes RJ, Gebski V, Coates AS, Harvey V, van Hazel G, 'Quality of life on single agent Mitozantrone versus Cyclophosphamide, Methotrexate, 5-fluorouracil, Prednisone for advanced breast cancer', Proceedings of the American Society of Clinical Oncology, 13 73 (1994)
1994FORBES JF, 'TOWARDS AN OPTIMAL TEACHING PROGRAM FOR SUPPORTIVE CARE', SUPPORTIVE CARE IN CANCER, 2 7-15 (1994)

DOI: 10.1007/BF00355234 | Author URL

Citations: Scopus - 13 | Web of Science - 13

1994Forbes J, Coates A, 'Clinical trials in breast cancer research and treatment', Cancer Forum, 18 81-84 (1994)

Citations: Scopus - 0

1994Forbes JF, 'Surgery of early breast cancer', Current Opinion in Oncology, 6 560-564 (1994)

Citations: Scopus - 0

1994Forbes JF, Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, et al., 'The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 Years Follow-up', Annals of Oncology, 5 717-724 (1994)

Citations: Scopus - 63

1994Forbes JF, Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam CM, et al., 'Present and Future Projects of the International Breast Cancer Study Group', Cancer, 74 1139-1149 (1994)

Citations: Scopus - 19

1994Forbes JF, 'Management of newly diagnosed early breast cancer a national approach to breast cancer control: Report from the National Breast Cancer Consensus Conference', Medical Journal of Australia, 161 s1-s16 (1994)
1994Forbes JF, 'Management of Newly Diagnosed Early Breast Cancer and a National Approach to Breast Cancer Control', Cancer Forum, 18 72-76 (1994)
1993Forbes JF, 'Surgery of early breast cancer', Current Opinion in Oncology, 5 966-975 (1993)

Citations: Scopus - 1

1993Forbes JF, Coates A, Simes RJ, 'Prognostic value of performance status and quality-of-life scores during chemotherapy for advanced breast cancer. The Australian New Zealand Breast Cancer Trials Group', Journal of Clinical Oncology, 11 2050 (1993)

Citations: Scopus - 11

1992ABE O, ABE R, ASAISHI K, ENOMOTO K, HATTORI T, INO Y, et al., 'SYSTEMIC TREATMENT OF EARLY BREAST-CANCER BY HORMONAL, CYTOTOXIC, OR IMMUNE THERAPY - 133 RANDOMIZED TRIALS INVOLVING 31000 RECURRENCES AND 24000 DEATHS AMONG 75000 WOMEN .2.', LANCET, 339 71-85 (1992)

Author URL

Citations: Web of Science - 839

1992FORBES JF, 'LONG-TERM EFFECTS OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER', ACTA ONCOLOGICA, 31 243-250 (1992)

Author URL

Citations: Scopus - 13 | Web of Science - 11

1992FORBES JF, 'CLINICAL-TRIALS AND LOCAL TREATMENT OF EARLY BREAST-CANCER', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 62 419-421 (1992)
1992Forbes J, 'The surgery of early breast cancer', Current Opinion in Oncology, 4 1027-1034 (1992)

Citations: Scopus - 0

1992FORBES JF, 'ESTROGEN AND BREAST-CANCER - REPLY', MEDICAL JOURNAL OF AUSTRALIA, 157 643-644 (1992)
1992Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, Forbes JF, 'Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer', Journal of Clinical Oncology, 10 1833-1838 (1992)

Citations: Scopus - 218

1992CLOVER KA, REDMAN S, FORBES JF, SANSONFISHER RW, DICKINSON JA, 'PROMOTION OF ATTENDANCE FOR MAMMOGRAPHIC SCREENING THROUGH GENERAL-PRACTICE - A RANDOMIZED TRIAL OF 2 STRATEGIES', MEDICAL JOURNAL OF AUSTRALIA, 156 91-94 (1992)

Author URL

Citations: Scopus - 13 | Web of Science - 12

Co-authors: Rob Sanson-Fisher

1991Forbes JF, Allbrook D, 'Education and palliative care: a different approach.', Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 121 414-422 (1991)

Citations: Scopus - 3

1991Forbes JF, 'Surgery for early breast cancer', Current Opinion in Oncology, 3 995-1001 (1991)

Citations: Scopus - 0

1991Low SC, Galea MH, Blamey RW, Goldhirsch A, Gelber RD, Forbes J, et al., 'Timing breast cancer surgery [1]', Lancet, 338 691-693 (1991)

DOI: 10.1016/0140-6736(91)91265-V

Citations: Scopus - 21

1991FORBES JF, 'TIMING OF BREAST-CANCER SURGERY IN THE MENSTRUAL-CYCLE AND OUTCOME', ANNALS OF ONCOLOGY, 2 243-243 (1991)

Author URL

Citations: Scopus - 1 | Web of Science - 3

1991Forbes JF, Foster HM, 'Optimizing palliative surgical support of cancer patients with visceral obstructions.', Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 121 108-114 (1991)

Citations: Scopus - 0

1990FORBES JF, 'SURGERY, KINETICS AND BIOLOGICAL CONSIDERATIONS IN PLANNING ADJUVANT THERAPY PROTOCOLS', EFFECTS OF THERAPY ON BIOLOGY AND KINETICS OF THE RESIDUAL TUMOR, PT A : PRE-CLINICAL ASPECTS, 354 133-146 (1990)

Author URL

Citations: Scopus - 0

1990SMART YC, STEWART JF, BARTLETT LD, BRIEN JH, FORBES JF, BURTON RC, 'MAMMARY SERUM ANTIGEN (MSA) IN ADVANCED BREAST-CANCER', BREAST CANCER RESEARCH AND TREATMENT, 16 23-28 (1990)

DOI: 10.1007/BF01806572 | Author URL

Citations: Scopus - 3 | Web of Science - 2

1990COATES A, FORBES J, 'CHANGING CONCEPTS IN THE MANAGEMENT OF CANCER .14. CLINICAL-TRIALS IN BREAST-CANCER IN AUSTRALIA AND NEW-ZEALAND', MEDICAL JOURNAL OF AUSTRALIA, 152 601-+ (1990)

Author URL

Citations: Web of Science - 2

1990Forbes JF, 'Surgery for early breast cancer', Current Opinion in Oncology, 2 1015-1024 (1990)

Citations: Scopus - 1

1989FORBES JF, 'INCREASED RISK OF BREAST-CANCER AFTER LOW-DOSE IRRADIATION', LANCET, 1 1012-1013 (1989)

Author URL

Citations: Scopus - 1 | Web of Science - 1

1988Forbes JF, 'Principles and potential of palliative surgery in patients with advanced cancer.', Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 108 134-142 (1988)

Citations: Scopus - 9

1988COATES A, BYRNE M, BISHOP JF, FORBES JF, 'INTERMITTENT VERSUS CONTINUOUS CHEMOTHERAPY FOR BREAST-CANCER - REPLY', NEW ENGLAND JOURNAL OF MEDICINE, 318 1468-1468 (1988)

Author URL

Citations: Web of Science - 12

1988TATTERSALL MHN, LANGLANDS AO, SIMPSON JS, FORBES JF, 'UNDERGRADUATE EDUCATION ABOUT CANCER - A SURVEY IN AUSTRALIAN MEDICAL-SCHOOLS', EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 24 467-471 (1988)

DOI: 10.1016/S0277-5379(98)90018-9 | Author URL

Citations: Scopus - 12 | Web of Science - 14

1988Plotkin D, Ray M, Coates A, Byrne M, Bishop JF, Forbes JF, 'Intermittent versus continuous chemotherapy for breast cancer', New England Journal of Medicine, 318 1467-1468 (1988)

Citations: Scopus - 1

1987Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, et al., 'Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies', New England Journal of Medicine, 317 1490-1495 (1987)

Citations: Scopus - 274

1987Forbes JF, 'The Nisbet Symposium 1986. Early breast cancer - An overview of current and future directions', Australasian Radiology, 31 113-118 (1987)

Citations: Scopus - 0

1986HORNE DJD, MCCORMACK HM, COLLINS JP, FORBES JF, RUSSELL IS, 'PSYCHOLOGICAL TREATMENT OF PHOBIC ANXIETY ASSOCIATED WITH ADJUVANT CHEMOTHERAPY', MEDICAL JOURNAL OF AUSTRALIA, 145 346-348 (1986)

Author URL

Citations: Scopus - 2 | Web of Science - 3

1986FORBES JF, 'A RANDOMIZED TRIAL IN POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER COMPARING ENDOCRINE AND CYTOTOXIC THERAPY GIVEN SEQUENTIALLY OR IN COMBINATION', JOURNAL OF CLINICAL ONCOLOGY, 4 186-193 (1986)

Author URL

Citations: Web of Science - 39

1984FORBES JF, 'FINE-NEEDLE ASPIRATION CYTOLOGY IN THE MANAGEMENT OF BREAST DISEASE', MEDICAL JOURNAL OF AUSTRALIA, 140 181-181 (1984)
1983SHUGG D, SHEPHERD JJ, BRAITHWAITE PA, CLUNIE GJ, FORBES JF, THOMPSON R, WOOLLEY T, 'DOCUMENTATION OF BREAST-CANCER FAMILY HISTORIES AND THE CONSTRUCTION OF FAMILY TREES FOR PEDIGREE ANALYSIS', MEDICAL AND PEDIATRIC ONCOLOGY, 11 216-216 (1983)
1983FORBES JF, 'BROMOCRIPTINE FOR BREAST PAIN', MEDICAL JOURNAL OF AUSTRALIA, 2 540-541 (1983)

Author URL

Citations: Scopus - 0

1982FORBES JF, 'MULTIMODALITY TREATMENT OF CANCER', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 52 341-346 (1982)
1982Forbes JF, 'Advanced breast cancer (and quality of life)', Clinics in Oncology, 1 917-944 (1982)

Citations: Scopus - 2

1982FORBES JF, 'ADJUVANT THERAPY IN BREAST-CANCER', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 52 414-417 (1982)

DOI: 10.1111/j.1445-2197.1982.tb06021.x | Author URL

Citations: Scopus - 0 | Web of Science - 1

1982Forbes JF, 'Breast cancer: Advanced disease', Clinics in Oncology, 1 149-175 (1982)

Citations: Scopus - 0

1981FORBES JF, 'BIOLOGICAL VERSUS STATISTICAL PLANNING OF CLINICAL-TRIALS', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 51 3-4 (1981)
1981FORBES JF, 'CONSIDERATIONS FOR A CLINICIAN BEFORE SUPPORTING A CLINICAL-TRIAL', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 51 4-5 (1981)
1981FORBES JF, ZBAR A, TAIT B, CLUNIE GJA, 'BREAST-CANCER GENETICS - ANALYSIS OF HLA ANTIGENS IN FAMILIAL AND NON FAMILIAL PATIENTS', PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 22 341-341 (1981)
1981FORBES JF, 'HIGHLIGHTS IN DEVELOPMENT OF RANDOMIZED CLINICAL-TRIALS', MEDICAL JOURNAL OF AUSTRALIA, 1 159-160 (1981)

Author URL

Citations: Web of Science - 2

1980Simpson J, Forbes JF, Gill G, 'Phase III trial for advanced breast cancer', Australian and New Zealand Journal of Surgery, 50 211-211 (1980)

Citations: Scopus - 0

1980LANGLANDS AO, FORBES JF, TATTERSALL MHN, 'THE TREATMENT OF LOCALLY ADVANCED BREAST-CANCER - A DISCUSSION DOCUMENT', AUSTRALASIAN RADIOLOGY, 24 307-310 (1980)

DOI: 10.1111/j.1440-1673.1980.tb02205.x | Author URL

Citations: Web of Science - 3

1980THOMAS RJS, FORBES JF, 'SOMATOSTATIN IN PEPTIC-ULCER BLEEDING', LANCET, 2 200-200 (1980)

Author URL

Citations: Scopus - 0 | Web of Science - 3

1980Forbes JF, 'Oestrogen receptors: Quality or quantity', Lancet, 1 828-829 (1980)

Citations: Scopus - 0

1980FORBES JF, 'ESTROGEN-RECEPTORS - QUALITY OR QUANTITY', LANCET, 1 828-829 (1980)
1979Kitchen PRB, Andrews JT, Buckley JD, Russell IS, Lichtenstein M, McLean K, Forbes JF, 'An analysis of bone scintigraphy in early (operable) breast cancer', Australian and New Zealand Journal of Surgery, 49 313-316 (1979)

Citations: Scopus - 1

1979FORBES JF, 'COLLEGE FOUNDATION', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 49 682-683 (1979)
1979FORBES JF, 'PROGRESS IN CANCER-THERAPY FROM CLINICAL-TRIALS', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 49 287-289 (1979)
1979NESBIT RA, WOODS RL, TATTERSALL MHN, FOX RM, FORBES JF, MACKAY IR, GOODYEAR M, 'TAMOXIFEN IN MALIGNANT-MELANOMA', NEW ENGLAND JOURNAL OF MEDICINE, 301 1241-1242 (1979)

Author URL

Citations: Scopus - 18 | Web of Science - 58

1979KITCHEN PRB, ANDREWS JT, BUCKLEY JD, RUSSELL IS, LICHTENSTEIN M, MCLEAN K, FORBES JF, 'ANALYSIS OF BONE-SCINTIGRAPHY IN EARLY (OPERABLE) BREAST-CANCER', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 49 313-316 (1979)

DOI: 10.1111/j.1445-2197.1979.tb07671.x | Author URL

Citations: Web of Science - 1

1978FORBES JF, MOORE AR, 'CONTROLLED TRIALS IN SURGERY', LANCET, 2 107-108 (1978)
1978HUGHES LE, FORBES JF, 'EARLY BREAST-CANCER .1. SURGICAL PATHOLOGY AND PREOPERATIVE ASSESSMENT', BRITISH JOURNAL OF SURGERY, 65 753-763 (1978)

DOI: 10.1002/bjs.1800651102 | Author URL

Citations: Scopus - 1 | Web of Science - 16

1978HUGHES LE, FORBES JF, 'EARLY BREAST-CANCER .2. MANAGEMENT', BRITISH JOURNAL OF SURGERY, 65 764-772 (1978)

DOI: 10.1002/bjs.1800651103 | Author URL

Citations: Scopus - 1 | Web of Science - 10

1977FORBES JF, 'EARLY DETECTION OF BREAST-CANCER', MEDICAL JOURNAL OF AUSTRALIA, 2 786-786 (1977)
1977TEASDALE C, FORBES JF, WEBSTER DJT, HUGHES LE, 'IMMUNE COMPETENCE IN BREAST, COLO-RECTAL, AND GASTRIC CANCER - CORRELATION OF PRETREATMENT AND SEQUENTIAL FOLLOW-UP TESTS', SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 6 753-754 (1977)
1977FORBES JF, 'MULTIMODAL THERAPY FOR STAGE-II BREAST-CANCER', LANCET, 2 1079-1079 (1977)
1977FORBES JF, 'GUIDELINES FOR PLANNING CLINICAL-TRIALS', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 47 628-636 (1977)

DOI: 10.1111/j.1445-2197.1977.tb06594.x | Author URL

Citations: Scopus - 0 | Web of Science - 2

1977FORBES JF, 'APPLICATION OF CLINICAL-TRIALS TO SOLID TUMOR MANAGEMENT - INTRODUCTION', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 47 617-627 (1977)

DOI: 10.1111/j.1445-2197.1977.tb06593.x | Author URL

Citations: Scopus - 0 | Web of Science - 1

1976TEASDALE C, FORBES JF, BAUM M, 'FAMILIAL MALE BREAST-CANCER', LANCET, 1 360-361 (1976)

Author URL

Citations: Scopus - 3 | Web of Science - 9

Show 202 more

Review (1 outputs)

YearCitationAltmetricsLink
2005Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, 'Meeting Highlights: International expert consensus on the primary therapy of early breast cancer 2005', Annals of Oncology (2005) [D1]

Citations: Scopus - 741

Conference (51 outputs)

YearCitationAltmetricsLink
2014Zdenkowski N, Butow P, Fewster S, Beckmore C, Wells K, Forbes JF, Boyle F, 'EXPLORING DECISION MAKING ABOUT NEOADJUVANT CHEMOTHERAPY FOR EARLY BREAST CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014)
2013Metzger Filho O, Giobbie-Hurder A, Mallon EA, Viale G, Winer EP, Thurlimann BJK, et al., 'Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2013) [E3]
2013Mathe A, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, Avery-Kiejda KA, 'Identification of biomarkers for metastatic spread in triple negative breast cancer.', Translational Cancer Research Conference Abstract booklet, Newcastle, Australia (2013) [E3]
2013Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, et al., 'Effect of Aromatase Inhibition on Bone Density and Bone Turnover in Healthy Postmenopausal Women: Results of the International Breast cancer Intervention Study II (IBIS-II)', JOURNAL OF BONE AND MINERAL RESEARCH, Baltimore, MD (2013) [E3]
2013Avery-Kiejda KA, Mathe A, Braye SG, Forbes JF, Scott RJ, 'The expression of Dicer and Drosha in lymph node metastases of triple negative breast cancer.', 25th Lorne Cancer Conference Proceedings, Lorne, VIC, Australia (2013) [E3]
2013Mathe A, Avery-Kiejda KA, Wong-Brown MW, Forbes JF, Braye SG, Scott RJ, 'Target gene identification of microRNAs associated with lymph node metastases in triple negative breast cancer.', 25th Lorne Cancer Conference Proceedings, Lorne, VIC, Australia (2013) [E3]
2013Mathe A, Avery-Kiejda KA, Wong-Brown M, Forbes JF, Braye SG, Scott RJ, 'Integration of microRNA and gene expression profiling in triple negative breast cancer to identify possible biomarkers for metastases.', Breakthrough Breast Cancer TNBC Conference Proceedings, London, UK (2013) [E3]
2012Phillips K-A, Kiely BE, Francis PA, Boyle FM, Fox SB, Murphy L, et al., 'ANZ1001 SORBET: Study of estrogen receptor beta and efficacy of tamoxifen, a single arm, phase II study of the efficacy of tamoxifen in triple-negative but estrogen receptor beta-positive metastatic breast cancer', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2012) [E3]
2012Kiejda KA, Forbes JF, Braye SG, Scott R, 'Identification of miRNAs associated with lymph node metastasis in triple-negative breast cancer', Human Genome Meeting 2012: Genetics and Genomics in Personalised Medicine. Abstract Book, Sydney, NSW (2012) [E3]
2011Singh S, Cuzick J, Blake GM, Mesher D, Patel R, Truscott J, et al., 'One year effect of anastrozole and risedronate on bone mineral density: First results from the IBIS-II bone sub-study', Bone, Sheffield, UK (2011) [E3]

DOI: 10.1016/j.bone.2010.10.064

Citations: Web of Science - 1

2011Kiejda KA, Forbes JF, Hope TL, Braye SG, Scott R, 'Differential expression of miRNAs in triple-negative breast cancer', AMATA Conference Canberra 2011 Handbook, Canberra, ACT (2011) [E3]
2011Kiejda KA, Forbes JF, Braye SG, Scott R, 'MicroRNA expression profiling in triple-negative breast cancer', Keystone Symposia on Mollecular and Cellular Biology: MicroRNAs and Non-coding RNAs and Cancer, Banff, AL (2011) [E3]
2010Wong-Brown M, Bowden NA, Forbes JF, Braye SG, Scott R, 'Microsatellite instability (I) in breast tumours', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
2010Kiejda KA, Forbes JF, Braye SG, Scott R, 'The relationship between p53 isofor and estrogen receptor-alpha expression in breast cancer', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
2009Dowsett M, Cuzick J, Wales C, Forbes J, Mallon L, Salter J, et al., 'Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study', CANCER RESEARCH, San Antonio, TX (2009) [E3]

Author URL

Citations: Web of Science - 8

2009Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, et al., 'Prognostic value of a combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and comparison with the GHI Recurrence Score: Results from TransATAC', Cancer Research, San Antonio, TX (2009) [E3]

Citations: Web of Science - 17

2009Forbes JF, Regan MM, Colleoni M, Giobbie-Hurder A, Thurlimann B, Mouridsen H, et al., 'Adjusting for Selective Crossover in Analysis of Letrozole (Let) versus Tamoxifen (tam) in the BIG 1-98 Trial', Cancer Research, San Antonio (2009) [E3]
2009Mackey J, Hurvitz S, Crown J, Forbes J, Roche H, Pinter T, et al., 'CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC)', CANCER RESEARCH, San Antonio, TX (2009) [E3]

Author URL

Citations: Web of Science - 1

2009Juraskova I, Butow P, Smith B, Seccombe MA, Coates A, Boyle FM, et al., 'Improving informed consent to prevention clinical trials: A randomised controlled trial of a decision aid for women invited to participate in IBIS-II', Asia-Pacific Journal of Clinical Oncology, Gold Coast, QLD (2009) [E3]
2009Gardner H, Nuciforo P, Liu W, Lee B, Rheinhardt J, Barrett C, et al., 'PI3 kinase pathway analysis in tissue microarrays using laser capture microdissection and immunohistochemistry', Cancer Research, San Antonio, TX (2009) [E3]
2009Bliss J, Kilburn L, Coleman R, Forbes JF, Coates A, Jones S, et al., 'Disease related outcome with long term follow-up: An updated analysis of the Intergroup Exemestane Study (IES)', Cancer Research, San Antonio, TX (2009) [E3]
2009Forbes JF, Mouridsen HT, Giobbie-Hurder A, Mauriac L, Paridaens R, Colleoni M, et al., 'BIG 1-98: A Randomized double-blind Phase III Study Evaluating Letrozole and Tamoxifen given in Sequence as Adjuvant Endocrine Therapy for Postmenopausal Women with Receptor-positive Breast Cancer', Cancer Research, San Antonio (2009) [E3]
2009Cuzick J, Sestak I, Pinder S, Ellis I, Hackshaw A, Bundred N, et al., 'Beneficial effect of tamoxifen for women with DCIS: Long-term results from the UK/ANZ DCIS Trial in women with locally excised DCIS', Cancer Research, San Antonio, TX (2009) [E3]

Citations: Web of Science - 2

2009Howell A, Forbes JF, Cuzick J, Atac Investigators, 'Initial adjuvant therapy with anastrozole - early- and late-event data from the arimidex, tamoxifen, alone or in combination (ATAC) trial in the hormone-responsive population', Breast, St Gallen, Switzerland (2009) [E3]
2009Martin M, Hurvitz S, Kennedy J, Forbes J, Roche H, Pinter T, et al., 'CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer (MBC)', EJC SUPPLEMENTS, Berlin, GERMANY (2009) [E3]
2009Sestak I, Distler W, Forbes JF, Howell A, Cuzick J, 'Effect of body mass index on recurrence in hormone receptor positive early breast cancer: A retrospective exploratory analysis from the ATAC Trial', Cancer Research, San Antonio, TX (2009) [E3]
2008Forbes JF, Cuzick J, Buzdar A, Howell A, Baum M, 'ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion', Breast Cancer Research and Treatment, San Antonio, TX (2008) [E3]
2008Grimison PS, Australian New Zealand Breast Cancer Trials Group, Coates AS, Forbes JF, Cuzick J, Furnival C, et al., 'Tamoxifen (TAM) for the prevention of breast cancer: Importance of specific aspects of health-related quality of life (HRQL) to global health status in the ANZ BCTG substudy of IBIS-1 (ANZ 92P1)', Journal of Clinical Oncology, Chicago, ILL (2008) [E3]
2008Sestak I, Forbes JF, Edwards R, Howell A, Cuzick J, 'Timing and severity of prominent side effects of anastrozole and tamoxifen', EJC Supplements, Berlin, Germany (2008) [E3]

Citations: Web of Science - 1

2007Pienkowski T, Pegram M, Forbes JF, Valero V, Eiermann W, Von Minckwitz G, et al., 'BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)', European Journal of Cancer Supplements (ECCO 14 Abstract Book), Barcelona, Spain (2007) [E3]
2007Juraskova I, Butow P, Lopez AL, Seccombe M, Smith B, Coates A, et al., 'Improving informed consent in clinical trials: A randomised controlled trial of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II)', Breast Cancer Research and Treatment, San Antonio, TX. (2007) [E3]
2007Forbes JF, Cuzick J, Buzdar A, Howell A, Baum M, 'ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion', Breast Cancer Research and Treatment, San Antonio, TX. (2007) [E3]

Citations: Web of Science - 1

2006Forbes JF, Pienkowski T, Valero V, Eiermann W, Von Minckwitz G, Martin M, et al., 'BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC)', Journal of Clinical Oncology (Vol 24, No 18S (June 20 Supplement), 2006: LBA516): 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Atlanta, Georgia (2006) [E3]

Citations: Web of Science - 1

2006Finn RS, Dering J, Ginther C, Press M, Forbes JF, Mackey J, et al., 'ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies (oral presentation)', Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I., Atlanta, Georgia (2006) [E3]

Citations: Web of Science - 5

2006Finn RS, Dering J, Ginther C, Wilson CA, Raab G, Pawlicki M, et al., 'Expression of EGFR ligands betacellulin and tenascin C are associated with molecular response following gefitinib treatment in women with primary breast cancer.', BREAST CANCER RESEARCH AND TREATMENT, San Antonio, TX (2006)
2006Gao JN, Warren R, Forbes JF, Warren-Forward H, D'Este C, 'Reproducibility of visual assessment of mammographic density.', BREAST CANCER RESEARCH AND TREATMENT, San Antonio, TX (2006)
2006Pienkowski T, Forbes J, Valero V, Eiermann W, Von Minckwitz G, Martin M, et al., 'BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)', ANNALS OF ONCOLOGY, Istanbul, TURKEY (2006)

Author URL

Citations: Web of Science - 1

2006Stockler MR, Sourjina T, Harvey V, Frances P, Byrne M, van Hazel G, et al., 'A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment.', BREAST CANCER RESEARCH AND TREATMENT, San Antonio, TX (2006)

Author URL

Citations: Web of Science - 7

Co-authors: Stephen Ackland

2006Gao JN, Forbes JF, Warren RML, Cuzick J, Howell A, D'Este C, Warren-Forward H, 'Change in marnmographic density after cessation of tamoxifen: results from international breast cancer intervention study I (IBIS I).', BREAST CANCER RESEARCH AND TREATMENT, San Antonio, TX (2006)
2006Reaby LL, Forbes JF, Snyder R, Young L, Coates A, 'The Australian New Zealand breast cancer trials group (ANZ BCTG) consumer advisory panel: building a powerful fellowship to increase participation in breast cancer clinical trials.', BREAST CANCER RESEARCH AND TREATMENT, San Antonio, TX (2006)
2006Forbes JF, Kennedy J, Pienkowski T, Valero V, Eiermann W, Von Minckwitz G, et al., 'BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC): Main time to progression (TTP) analysis.', JOURNAL OF CLINICAL ONCOLOGY, Atlanta, GA (2006)

Author URL

Citations: Web of Science - 4

2006Sestak I, Forbes J, Roseann K, Edwards R, Howell A, Cuzick J, 'Comparison of side-effect profiles during active treatment versus follow-up in the IBIS-1 tamoxifen prevention study.', BREAST CANCER RESEARCH AND TREATMENT, San Antonio, TX (2006)
2005Francis P, Green M, Gebski V, Harvey V, Karapetis C, Chan A, et al., 'Gefitinib has a low clinical benefit rate in advanced breast cancer patients.', BREAST CANCER RESEARCH AND TREATMENT, San Antonio, TX (2005)
2004Thompson JD, Warren-Forward H, Bennett M, Lai MK, Brown RL, Moran SM, Forbes JF, 'Step one of a feasibility study into the reduction of recall rates in screening mammography', Australian Institute of Radiography 1st Annual Scientific Meeting of Medical Imaging and Radiation Therapy, Cairns, Australia (2004) [E3]
2004Forbes JF, Seccombe MA, 'Prevention and treatment trials need different recruitment strategies: Experience from the IBIS 1 prevention trial in Australia and New Zealand.', JOURNAL OF CLINICAL ONCOLOGY, New Orleans, LA (2004)
2004McKillop D, Raab G, Eidtmann H, Furnival A, Riva A, Forbes J, et al., 'Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103)', JOURNAL OF CLINICAL ONCOLOGY, New Orleans, LA (2004)

Author URL

Citations: Web of Science - 1

2002Forbes JF, Colleoni M, Zahrieh D, Nole F, Gelber RD, Castilglione-Gertsch M, et al., 'Is Medial Breast Cancer without Axillary Node involvement really Node-Negative?', ASCO 2002 Abstracts, Orlando (2002)
2002Forbes JJ, Travis E, Forbes JF, Woodhead J, Toirkens M, Knight A, 'Targeted interventions can improve rescreen compliance in a regional mammographic screening program.', BREAST CANCER RESEARCH AND TREATMENT, SAN ANTONIO, TX (2002)
2000Ackland S, Gebski V, Wilson A, Green M, Hornery S, Dhillon H, et al., 'High Dose Epirubicin & Cyclophosphamide (HDEC) with Filgrastim versus Standard Dose (SDEC) in Advanced Breast Cancer - A Quality of Life Study by the ANZ Breast Cancer Trials Group', Proceedings of the Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, USA (2000) [E3]
2000Castiglione-Gertsch M, Price K, Nasi M, Lindtner J, Erzen D, Crivellari D, et al., 'Is the addition of Adjuvant Chemotherapy Always Necessary in Node Negative (N-) Postmenopausal Breast Cancer Patients (Pts) Who Receive Tamoxifen (TAM)?: First Results of IBCSG Trial IX', Proceedings of the Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, USA (2000) [E3]
1993Forbes JF, Australian New Zealand Breast Cancer Trials Group, 'Breast Cancer Prevention: a National Clinical Trial [invited abstract]', Proceedings of the RACS Annual Scientific Meeting 1993, Adelaide (1993)
Show 48 more
Edit

Grants and Funding

Summary

Number of grants49
Total funding$30,168,064

- Indicates that the researcher may be seeking students for this project.

Click on a grant title below to expand the full details for that specific grant.

2014 (2 grants)

Randomised phase II trial of neoadjuvant chemotherapy +/- concurrent aromatase inhibitor endocrine therapy to down-stage large oestrogen receptor positive breast cancer$2,219,383
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Conjoint Associate Professor Prudence Francis, Associate Professor Nicholas Wilcken, Dr Nicholas Murray, Professor John Forbes, Associate Professor Andrew Redfern, Associate Professor Frances Boyle, Associate Professor Andrew Spillane
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$2,219,38320142019
GNo:G1300307

High Throughput Image Capture Platform for Translational Cancer Research$282,614
Funding Body: Cancer Institute NSW

Project Team
Conjoint Professor Stephen Ackland, Professor Rodney Scott, Professor John Forbes, Professor Xu Dong Zhang, Professor Marjorie Walker, Professor Hubert Hondermarck, Doctor Craig Gedye, Doctor Rick Thorne, Mr Loui Rassam, Doctor Stephen Braye
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$282,61420142014
GNo:G1400626

2013 (5 grants)

Enabling Clinical Epigenetic Diagnostics: The Next Generation of Personalized Breast Cancer Care$605,301
Funding Body: National Breast Cancer Foundation

Project Team
Professor Matt Trau, Assoc. Prof Glenn Francis, Assoc. Prof Susan Clark, Professor John Forbes, Dr Melissa Brown, Professor Alexander Dobrovic, Professor Rodney Scott
SchemeRole
Collaborative Breast Cancer Research Grant ProgramChief Investigator
Total AmountFunding StartFunding Finish
$605,30120132017
GNo:G1201095

IBIS 3: Preventing late recurrence of ER positive breast cancer in postmenopausal women – a comprehensive approach$10,000
Funding Body: Hunter Medical Research Institute

Project Team
Professor John Forbes
SchemeRole
Near MissChief Investigator
Total AmountFunding StartFunding Finish
$10,00020132013
GNo:G1300655

IBIS 3: Preventing late recurrence of ER positive breast cancer in postmenopausal women – a comprehensive approach$10,000
Funding Body: University of Newcastle

Project Team
Professor John Forbes
SchemeRole
Near Miss GrantChief Investigator
Total AmountFunding StartFunding Finish
$10,00020132013
GNo:G1300481

Mammographic Density as a Biomarker for Clinical Trial Treatment Efficacy$6,000
Funding Body: Calvary Mater Newcastle

Project Team
Professor John Forbes, Mrs Judith Jobling
SchemeRole
ScholarshipChief Investigator
Total AmountFunding StartFunding Finish
$6,00020132013
GNo:G1301065

2012 EIA Impact Trial travel grant$2,000
Funding Body: University of Newcastle

Project Team
Professor John Forbes
SchemeRole
Travel GrantChief Investigator
Total AmountFunding StartFunding Finish
$2,00020132013
GNo:G1300371

2012 (2 grants)

Medilink Array digitising system$35,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes
SchemeRole
Equipment GrantChief Investigator
Total AmountFunding StartFunding Finish
$35,00020122012
GNo:G1100981

Longitudinal changes in mammographic density as a biomarker for future breast cancer events$24,360
Funding Body: Hunter Medical Research Institute

Project Team
Professor John Forbes, Conjoint Professor Cate d'Este, Ms Judith Jobling
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$24,36020122012
GNo:G1200833

2011 (3 grants)

Hunter translational cancer research unit$1,693,333
Funding Body: Cancer Institute NSW

Project Team
Conjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Laureate Professor Robert Sanson-Fisher, Conjoint Associate Professor Anthony Proietto, Professor Rodney Scott
SchemeRole
Translational Cancer Research UnitInvestigator
Total AmountFunding StartFunding Finish
$1,693,33320112014
GNo:G1100545

Targeting Breast Cancer Recurrence Through Epithelial Mesenchymal Plasticity$56,717
Funding Body: National Breast Cancer Foundation

Project Team
Associate Professor Erik Thompson, Associate Professor Gregory Goodall, Professor Christobel Saunders, Associate Professor Robin Anderson, Assoc. Prof Alpha Yap, Dr Ian Street, Professor Keith Stanley, Dr Anthony Dowling, Professor John Forbes
SchemeRole
Collaborative Breast Cancer Research Grant ProgramChief Investigator
Total AmountFunding StartFunding Finish
$56,71720112013
GNo:G1101075

p53 isoforms, a prognostic indicator in breast cancer?$45,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Kelly Kiejda, Professor Rodney Scott, Professor John Forbes
SchemeRole
Breast Cancer Project GrantInvestigator
Total AmountFunding StartFunding Finish
$45,00020112011
GNo:G1001006

2010 (2 grants)

Mammographic density as a biomarker for the efficacy of treatment of endocrine therapies used to prevent breast cancer events in randomised controlled clinical trials$55,016
Funding Body: Cancer Institute NSW

Project Team
Professor John Forbes, Mrs Judith Jobling
SchemeRole
Research Scholars AwardChief Investigator
Total AmountFunding StartFunding Finish
$55,01620102012
GNo:G1000482

The identification of microRNA's as therapeutic targets for the treatment of advanced breast cancer$21,600
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Kelly Kiejda, Professor Rodney Scott, Professor John Forbes
SchemeRole
Research GrantInvestigator
Total AmountFunding StartFunding Finish
$21,60020102010
GNo:G0900144

2009 (2 grants)

IBIS II: A randomised phase III trail of anastrozole for breast cancer prevention in postmenopausal women at high risk$1,635,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Associate Professor Frances Boyle, Professor Gregory Mann, Professor Christobel Saunders, Professor Jack Cuzick
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$1,635,00020092013
GNo:G0188905

Provision of non-physical infrastructure support to enhance the breast cancer clinical trials research activities of the ANZ BCTG and its ability to build productive research collaborations$330,000
Funding Body: Cancer Institute NSW

Project Team
Professor John Forbes, Associate Professor Frances Boyle, Conjoint Professor Stephen Ackland, Professor Alan Coates
SchemeRole
Infrastructure GrantsChief Investigator
Total AmountFunding StartFunding Finish
$330,00020092012
GNo:G0190219

2008 (5 grants)

Prevention of late breast cancer (BC) events in postmenopausal women with endocrine responsive BC$4,430,875
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Gregory Mann, Associate Professor Frances Boyle, Assoc. Prof Michael Green, Professor Alan Coates, Professor Jack Cuzick
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$4,430,87520082012
GNo:G0187682

Novel strategies for prediction and control of advanced breast cancer via nanoscaled epigenetic-based biosensors$1,200,000
Funding Body: National Breast Cancer Foundation

Project Team
Professor John Forbes, Professor Rodney Scott, Professor Matt Trau, Assoc. Prof Susan Clark, Dr Melissa Brown, Assoc. Prof Glenn Francis, Professor Alexander Dobrovic
SchemeRole
Collaborative Breast Cancer Research Grant ProgramChief Investigator
Total AmountFunding StartFunding Finish
$1,200,00020082012
GNo:G0188685

HMRI Cancer Research Program - MRSP Infrastructure$1,031,290
Funding Body: Hunter Medical Research Institute

Project Team
Conjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Conjoint Professor Jim Denham, Conjoint Professor Peter Hersey, Professor Gordon Burns, Professor Adam McCluskey, Doctor Nikki Verrills
SchemeRole
NSW MRSP Infrastructure GrantInvestigator
Total AmountFunding StartFunding Finish
$1,031,29020082009
GNo:G0188622

Tailored treatments for premenopausal women with endocrine responsive breast cancer$287,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Dr Prudence Francis, Associate Professor Frances Boyle, Dr Jacqueline Chirgwin, Dr R Snyder, Professor Alan Coates
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$287,00020082010
GNo:G0187683

Support Funds for two clinical breast cancer trials: LATER and IBIS II$15,000
Funding Body: Hunter Medical Research Institute

Project Team
Professor John Forbes
SchemeRole
Sparke Helmore/NBN Television Corporate Triathlon Award for Research ExcellenceChief Investigator
Total AmountFunding StartFunding Finish
$15,00020082008
GNo:G0189429

2007 (2 grants)

Cognitive Function substudy for the SOFT trial$284,450
Funding Body: National Health & Medical Research Council

SchemeRole
Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$284,45020072007
GNo:17791600

A clinical trial evaluating neoadjuvant chemotherapy for women with large operable or locally advanced breast cancer$259,500
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Professor Michael Friedlander, Associate Professor Nicole McCarthy, Dr Anne Hamilton, Assoc. Prof Michael Green
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$259,50020072009
GNo:G0186405

2006 (3 grants)

Follow-up of a randomised trial of Tamoxifen or placebo for breast cancer prevention in high risk women$861,143
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr R Snyder, Professor Jack Cuzick
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$861,14320062010
GNo:G0185154

Infrastructure support for the ANZ BCTG clinical trials program$720,530
Funding Body: Cancer Australia

SchemeRole
Infrastructure support for clinical trials programChief Investigator
Total AmountFunding StartFunding Finish
$720,53020062007
GNo:17784169

PRC - Priority Research Centre for Bioinformatics, Biomarker Discovery & Information-Based Medicine (CIBM)$621,143
Funding Body: University of Newcastle

Project Team
Professor Pablo Moscato, Professor Rodney Scott, Emeritus Professor John Rostas, Professor John Forbes, Conjoint Professor Peter Hersey, Conjoint Professor Stephen Ackland, Conjoint Professor Wayne Smith, Emeritus Professor Peter Dunkley, Emeritus Professor Leonie Ashman, Professor John Attia, Associate Professor Phillip Dickson, Associate Professor Liz Milward, Professor Alistair Sim, Associate Professor Paul Tooney, Associate Professor Regina Berretta, Conjoint Professor David Sibbritt, Conjoint Professor Chris Levi, Professor Xu Dong Zhang, Conjoint Associate Professor Patricia Crock, Conjoint Associate Professor Jeannette Lechner-Scott
SchemeRole
Priority Research CentreInvestigator
Total AmountFunding StartFunding Finish
$621,14320062013
GNo:G0186919

2005 (5 grants)

Protocol development, web-based data collection and date quality assurance for all Cancer Cooperative Trials Groups$1,840,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Conjoint Professor Stephen Ackland, Professor Alan Coates, Professor John Zalcberg, Professor Max Wolf, Dr Kwun Fong, Professor John Forbes, Dr Helen Irving, Dr Guy Toner, Professor Michael Friedlander, Professor John Thompson, Dr David Ball, Professor John Simes
SchemeRole
Enabling Grants - Clinical Trials ResourcesInvestigator
Total AmountFunding StartFunding Finish
$1,840,00020052010
GNo:G0184628

Enhancement of the ANZBCTG research program through the provision of infrastructure funding for essential management and operational personnel and other key activities $1,720,564
Funding Body: Cancer Institute NSW

Project Team
Professor John Forbes, Professor Alan Coates, Professor John Simes, Conjoint Professor Stephen Ackland
SchemeRole
Infrastructure GrantsChief Investigator
Total AmountFunding StartFunding Finish
$1,720,56420052009
GNo:G0185068

Tailored treatments for pre-menopausal patients with endocrine responsive breast cancer$253,314
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr R Snyder, Dr Prudence Francis
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$253,31420052007
GNo:G0184207

Follow-up of women on a randomised clinical trial of adjuvant docetaxel and doxorubicin for node positive breast cancer$111,750
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr R Snyder, Dr Prudence Francis
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$111,75020052007
GNo:G0183940

2005 RIBG allocation$65,000
Funding Body: University of Newcastle

Project Team
Professor John Forbes
SchemeRole
Research Infrastructure Block Grant (RIBG)Chief Investigator
Total AmountFunding StartFunding Finish
$65,00020052005
GNo:G0185796

2004 (2 grants)

NSW Tissue Bank$2,000,000
Funding Body: National Health & Medical Research Council

SchemeRole
Enabling GrantInvestigator
Total AmountFunding StartFunding Finish
$2,000,00020042007
GNo:17790375

A randomised phase III trial of anastrozole for breast cancer prevention in postmenopausal women at high risk$1,566,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr R Snyder, Dr M Byrne
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$1,566,00020042008
GNo:G0182881

2002 (1 grants)

Follow-up phase of a randomised trial of Tamoxifen or placebo for breast cancer prevention in high risk women$450,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr R Snyder, Dr M Byrne
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$450,00020022004
GNo:G0180884

2001 (1 grants)

Randomised trials of adjuvant cytotoxic & endocrine therapy for early N+ and N- breast cancer.$510,095
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr J Collins, Dr M Byrne
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$510,09520012003
GNo:G0179671

2000 (1 grants)

Clinical trial of adjuvant docetaxel and doxorubicin for node positive breast cancer.$182,187
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr R Snyder, Dr Prudence Francis
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$182,18720002002
GNo:G0178482

1998 (3 grants)

Randomised trial of tamoxifen or placebo for breast cancer prevention in high risk women$1,541,046
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr R Snyder, Dr M Byrne
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$1,541,04619982000
GNo:G0177167

Clinical trial of optimal chemotherapy in poor prognosis node positive early breast cancer$195,222
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Assoc. Prof Michael Green, Dr M Byrne
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$195,22219982000
GNo:G0177166

Optimal endocrine and cytotoxic adjuvant therapy for node negative operable breast cancer$173,154
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr R Snyder, Dr J Collins
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$173,15419982000
GNo:G0177165

1995 (4 grants)

95APP. Randomised trial of tamoxifen and placebo for breast cancer prevention in high risk women.$1,476,004
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr R Snyder
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$1,476,00419951997
GNo:G0174578

Optimal endocrine and cytotoxic adjuvant therapy for node negative operable breast cancer.$348,825
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr R Snyder
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$348,82519951997
GNo:G0174579

Surgical Oncology$35,000
Funding Body: Department of Education, Training & Youth Affairs

Project Team
Professor John Forbes
SchemeRole
Research Infrastructure Block Grant (RIBG)Chief Investigator
Total AmountFunding StartFunding Finish
$35,00019951995
GNo:G0175586

95APP. Applied biosystems 373 automated DNA sequencer and genotyper.$30,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Gordon Burns, Professor Judith Scott
SchemeRole
Equipment GrantChief Investigator
Total AmountFunding StartFunding Finish
$30,00019951995
GNo:G0174612

1994 (1 grants)

Clinical trials of adjuvant chemo and hormone therapy in early breast cancer.$313,346
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor Alan Coates, Dr M Byrne, Dr R Snyder
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$313,34619941996
GNo:G0173010

1993 (1 grants)

93,94,95 GRANT. Randomised Trial of Local Treatment & Tamoxifen for In Situ Breast Cancer.$51,800
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Professor David Joseph, Dr J Collins, Professor Alan Coates
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$51,80019931995
GNo:G0173167

1992 (1 grants)

Clinical trials for prevention and treatment of breast cancer.$293,410
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes, Dr M Byrne, Dr J Collins, Professor Alan Coates
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$293,41019921994
GNo:G0174266

1991 (3 grants)

Clinical Trials Of Adjuvant Therapy In Node Positive Breast Cancer$199,859
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$199,85919911993
GNo:G0174251

Adjuvant Therapy Trial For Node Negative Patients With Early Operable Breast Cancer$61,733
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor John Forbes
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$61,73319911991
GNo:G0173951

Treatment Of Early Pre Invasive And Invasive Breast Cancer$7,500
Funding Body: Royal Australasian College of Surgeons

Project Team
Professor John Forbes
SchemeRole
Foundation Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$7,50019911991
GNo:G0173997
Edit

Research Supervision

Number of current supervisions1
Total current UoN PhD EFTSL0.4

For supervisions undertaken at an institution other that the University of Newcastle, the institution name is listed below the program name.

Current Supervision

CommencedProposed
Completion
ProgramSupervisor TypeResearch Title
20102014PhD (CommunityMed & ClinEpid)Principal SupervisorMammographic Density as a Biomarker for the Efficacy of Treatment of Endocrine Therapies Used to Prevent Breast Cancer Events in Randomised Controlled Clinical Trials

Past Supervision

YearProgramSupervisor TypeResearch Title
2007PhD (Surgical Science)Principal SupervisorThe Effect of Tamoxifen on Mammographic Density in Women with High Risk of Breast Cancer
Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

CountryCount of Publications
Australia165
United Kingdom99
United States90
Italy52
Switzerland48
More...
Edit

Professor John Forbes

Work Phone(02) 4985 0113
Fax(02) 4960 1539
Email
PositionProfessor
School of Medicine and Public Health
Faculty of Health and Medicine
The University of Newcastle, Australia
Office
2.041,
NBN Telethon Mater Institute,
Calvary Mater Newcastle Hospital
URL:www.newcastle.edu.au/profile/john-forbes